Kornfeld-Sylla, Sara S. https://orcid.org/0009-0003-6027-9453
Gelegen, Cigdem
Norris, Jordan E. https://orcid.org/0000-0002-4438-3416
Chaloner, Francesca A. https://orcid.org/0000-0003-2707-4539
Lee, Maia
Khela, Michael https://orcid.org/0009-0003-4838-3012
Heinrich, Maxwell J.
Finnie, Peter S. B.
Ethridge, Lauren E.
Erickson, Craig A.
Schmitt, Lauren M.
Cooke, Sam F.
Wilkinson, Carol L. https://orcid.org/0000-0002-4694-8564
Bear, Mark F. https://orcid.org/0000-0002-9903-2541
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1K23DC017983-01A1)
U.S. Department of Health & Human Services | National Institutes of Health (1T32MH112510)
U.S. Department of Health & Human Services | National Institutes of Health (U54HD082008)
U.S. Department of Health & Human Services | National Institutes of Health (U54HD104461)
U.S. Department of Health & Human Services | National Institutes of Health (K23 HD101416)
U.S. Department of Health & Human Services | National Institutes of Health (F31 HD113221-01A1)
U.S. Department of Health & Human Services | National Institutes of Health (R01EY023037)
U.S. Department of Health & Human Services | National Institutes of Health (R21NS123499)
National Science Foundation (GRFP)
FRAXA Research Foundation
Autism Science Foundation
Thrasher Research Fund
Harvard Catalyst
Simons Foundation (SFARI 575135)
RCUK | Biotechnology and Biological Sciences Research Council (BB/S008276/1)
Article History
Received: 3 April 2025
Accepted: 28 January 2026
First Online: 9 February 2026
Competing interests
: M.F.B. is a co-founder of Allos Pharma, developing Arbaclofen for the treatment of Fragile X syndrome. The remaining authors declare no competing interests.